Fourpath Capital Management’s AbbVie ABBV Stock Holding History

Fourpath Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.79M	Buy	7,115 +1,714	+32%	+$369K	0.24%	78
2026 Q1	$1.17M	Sell	5,401 -50	-0.9%	-$11.1K	0.17%	95
2025 Q4	$1.25M	Sell	5,451 -2,706	-33%	-$616K	0.17%	90
2025 Q3	$1.89M	Sell	8,157 -16	-0.2%	-$3.26K	0.27%	72
2025 Q2	$1.52M	Buy	8,173 +454	+6%	+$84.4K	0.24%	76
2025 Q1	$1.62M	Buy	7,719 +293	+4%	+$57K	0.28%	71
2024 Q4	$1.32M	Buy	7,426 +876	+13%	+$161K	0.24%	81
2024 Q3	$1.29M	Buy	6,550 +406	+7%	+$75.8K	0.24%	80
2024 Q2	$1.05M	Sell	6,144 -314	-5%	-$52K	0.78%	23
2024 Q1	$1.18M	Sell	6,458 -2,229	-26%	-$384K	0.82%	23
2023 Q4	$1.35M	Buy	8,687 +582	+7%	+$84.8K	0.91%	19
2023 Q3	$1.21M	Sell	8,105 -215	-3%	-$31.6K	0.91%	25
2023 Q2	$1.12M	Sell	8,320 -1,231	-13%	-$181K	1.35%	19
2023 Q1	$1.52M	Sell	9,551 -456	-5%	-$69.7K	1.07%	15
2022 Q4	$1.62M	Sell	10,007 -418	-4%	-$64.1K	1.18%	15
2022 Q3	$1.4M	Sell	10,425 -718	-6%	-$103K	0.96%	22
2022 Q2	$1.71M	Sell	11,143 -3,872	-26%	-$592K	1.06%	17
2022 Q1	$2.43M	Sell	15,015 -1,595	-10%	-$232K	0.97%	22
2021 Q4	$2.25M	Buy	+16,610	New	+$1.96M	0.86%	20

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fourpath Capital Management's ABBV Position: Q2 2026 in Review

Fourpath Capital Management increased its AbbVie (ABBV) stake by 32% in Q2 2026, buying an estimated $369K and bringing the position to 7,115 shares worth $1.79M. The position accounts for 0.24% of the portfolio, ranked #78.

Fourpath Capital Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.43M in Q1 2022. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Fourpath Capital Management held 7,115 shares of AbbVie worth $1.79M as of Q2 2026.
Fourpath Capital Management bought 1,714 AbbVie shares in Q2 2026, an estimated $369K.
AbbVie made up 0.24% of Fourpath Capital Management's portfolio in Q2 2026, its #78 holding.
Fourpath Capital Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
Fourpath Capital Management's AbbVie position peaked at $2.43M in Q1 2022.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fourpath Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.